Goldman Sachs analyst Paul Choi started Biohaven Pharmaceutical with a Buy rating and $92 price target. The analyst believes Biohaven will become a “more significant presence in the attractive” calcitonin gene-related peptide/migraine space than is currently priced into the shares. Rimegepant’s profile can drive above consensus sales on conservative patient numbers, Choi tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.